Performance of different biomarkers for the management of hepatocellular carcinoma

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the second cause of cancer related death due to latent liver disease, late diagnosis and non-available therapeutic treatment. Liver biopsy is still the gold standard in order to know the molecular biology of the tumor, its behaviour and invasive characteristics. Conventional diagnosis methods for HCC detection include imaging and serological tests with low sensitivity and specificity. In this review, we focus on the potential utility of certain serum biomarkers and a new approach, “liquid biopsy”, in the management of HCC patients.

Keywords

Hepatocellular carcinoma / liver biopsy / conventional diagnostic methods / management

References

[1] Organization World Health. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available from: http://globocan.iarc.fr/Default.aspx. [Last accessed on 27 Jun]

[2] Malvezzi M,Levi F,Negri E.European cancer mortality predictions for the year 2012.Ann Oncol2012;23:1044-52

[3] Ronot M,Wassermann J,Dreyer C,Castera L,Belghiti J,Faivre S.Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib..Oncologist2014;19:394-402 PMCID:PMC3983809

[4] Sterling RK,Gordon F,Reddy KR,Kanke F,Sherman M.Utility of lens culinaris agglutinin-reactive fraction of α-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.Clin Gastroenterol Hepatol2009;7:104-13

[5] Debruyne EN.Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications.Clin Chim Acta2008;395:19-26

[6] Zhang BH,Tang ZY.Randomized controlled trial of screening for hepatocellular carcinoma.J Cancer Res Clin Oncol2004;130:417-22

[7] Chayvialle JAP.Radioimmunoassay of alpha-fetoprotein in human plasma.Lancet1973;301:1355-7

[8] Lok AS,Everhart JE,Hoefs JC,Morgan TR,Lee WM,Dienstag JL.Des-γ-carboxy prothrombin and α-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma.Gastroenterology2010;138:493-502 PMCID:PMC2819612

[9] Marrero JA,Wang Y,Befeler AS,Reddy KR,Llovet JM,Dalhgren J,Lok AS,Srivastava S.α-fetoprotein, des-γ carboxyprothrombin, and lectin-bound α-fetoprotein in early hepatocellular carcinoma.Gastroenterology2009;137:110-8 PMCID:PMC2704256

[10] Heimbach JK,Finn RS,Abecassis MM,Zhu AX,Marrero JA.AASLD guidelines for the treatment of hepatocellular carcinoma.Hepatology2018;67:358-80

[11] Llovet JM,Lencioni R,Galle PR,Greten TF,Roskams T,Ducreux M,Bernardi M,Colombo M.EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.J Hepatol2012;56:908-43

[12] Singal AG,Tiro J.Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis.PLoS Med2014;11:e1001624 PMCID:PMC3972088

[13] She WH,Cheung TT,Chok KSH.Survival outcomes of liver transplantation for hepatocellular carcinoma in patients with normal, high and very high preoperative alpha-fetoprotein levels.World J Hepatol2018;10:308-18 PMCID:PMC5838449

[14] Toyoda H,Kiriyama S,Tanikawa M,Hayashi K,Kitabatake S,Nonogaki K,Shimizu J.Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan.Cancer2004;100:2415-21

[15] Tsuchiya N,Endo I,Uemura Y.Biomarkers for the early diagnosis of hepatocellular carcinoma.World J Gastroenterol2015;21:10573-83 PMCID:PMC4588079

[16] Spangenberg HC,Blum HE.Serum markers of hepatocellular carcinoma.Semin Liver Dis2006;26:385-90

[17] Li D,Satomura S.AFP-L3: a new generation of tumor marker for hepatocellular carcinoma.Clin Chim Acta2001;313:15-9

[18] Abdel-Aziz MM,Abass AT,Ezzat S.Comparison of AFP-L3 and p53 antigen concentration with alpha-fetoprotein as serum markers for hepatocellular carcinoma.Clin Lab2016;62:1121-9

[19] Oda K,Tamai T,Kumagai K,Saishoji A,Ohno K,Imanaka D,Uto H,Hashiguchi T.Highly sensitive lens culinaris agglutinin-reactive α-fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease.Oncol Rep2011;26:1227-33

[20] Yi X,Bao Y.Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis.Clin Chim Acta2013;425:212-20

[21] Bertino G,Boemi PM,Interlandi D,Minona E,Vicari S,Puleo S.A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma.Panminerva Med2008;50:221-6

[22] Okuda H,Takatsu K,Hayashi N,Takasaki K.Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for α-fetoprotein alone and those seropositive for des-γ-carboxy prothrombin alone.Gastroenterol Hepatol2001;16:1290-6

[23] Hong YM,Yoon KT,Yang KH,Rhu JH.Risk factors of early recurrence after curative hepatectomy in hepatocellular carcinoma.Tumor Biol2017;39:1-9

[24] Hamamura K,Shiina S,Obi S,Yoshida H.Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein.Cancer2000;88:1557-64

[25] Bertino G,Calvagno GS,Boemi PM.Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer.Drug News Perspect2010;23:498-508

[26] Suehiro T,Itasaka H,Yamamoto K.Des-gamma-carboxy prothrombin and proliferative activity of hepatocellular carcinoma.Surgery1995;117:682-91

[27] Sung YK,Park MK,Han IS,Kim JC.Glypican-3 is overexpressed in human hepatocellular carcinoma.Cancer Sci2003;94:259-62

[28] Liu XF,Liu XC,Ding CM.Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: a systematic review and meta-analysis.Clin Biochem2014;47:196-200

[29] Tahon AM,Zaky S,Bersy AM,E AZ,Johar D.Significance of glypican-3 in early detection of hepatocellular carcinoma in cirrhotic patients.J Gastrointest Cancer2018;

[30] El-Saadany S,Helmy A,El-Sayed Hussein B,Elmashad N,Basha EA.Diagnostic value of glypican-3 for hepatocellular carcinomas.Asian Pac J Cancer Prev2018;19:811-7 PMCID:PMC5980860

[31] Libbrecht L,Cassiman D,Pirenne J,Verslype C,Roskams T.Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.Am J Surg Pathol2006;30:1405-11

[32] Capurro MI,Lobe C.Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling.Cancer Res2005;65:6245-54

[33] Filmus J.Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma.FEBS J2013;280:2471-6

[34] Abou-Alfa GK,Hsu CH,Beylergil V,Pandit-Taskar N,Lyashchenko SK,Wan P,Lin ZZ,O'Neil B,Smith-Jones PM,Tanaka T,Maki Y,Chen YC.Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC).Cancer Chemother Pharmacol2017;79:421-9 PMCID:PMC5548107

[35] Ikeda M,Okusaka T,Kobayashi S,Suzuki I,Furuse J.Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma.Cancer Sci2014;105:455-62 PMCID:PMC4317809

[36] Abou-Alfa GK,Daniele B,Merle P,Ross P,Ebert O,Poon TP,Okusaka T,Minguez B,Ohtomo T,Boisserie F,Chen YC,Shochat E,Reis B,Di Laurenzio L,Yen CJ.Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.J Hepatol2016;65:289-95

[37] Wu Q,Le Trinh T,Xia M,Hou Z,Puszyk W,Nelson DR,Ostrov D,Xia CQ.A novel vaccine targeting glypican-3 as a treatment for hepatocellular carcinoma.Mol Ther2017;25:2299-308

[38] Sawada Y,Nobuoka D,Kuronuma T,Mizuno S,Nakachi K,Nakagohri T,Gotohda N,Yamao K,Furuse J,Nakatsura T.Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.Clin Cancer Res2012;18:3686-96

[39] Tsuchiya N,Fujinami N,Mizuno S,Endo I.Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma.Oncoimmunology2017;6:e1346764 PMCID:PMC5665076

[40] Sun Y,Zong WX.SERPINB3 and B4: from biochemistry to biology.Semin Cell Dev Biol2017;62:170-7 PMCID:PMC5318283

[41] Pontisso P,Benvegnù L,Belluco C,De Falco S,Valente M,Gatta A.Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma.Br J Cancer2004;90:833-7 PMCID:PMC2410161

[42] Turato C,Simonato D,Morello E,Quarta S,Ruvoletto M,Fasolato S,Cillo U,Parola M.SerpinB3 and Yap interplay increases Myc oncogenic activity.Sci Rep2015;5:17701 PMCID:PMC4669520

[43] Pontisso P.Role of SERPINB3 in hepatocellular carcinoma.Ann Hepatol2014;13:722-7

[44] Biasiolo A,Fasolato S,Martini A,Fassina G,Gatta A.Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: a prospective study.Dig Liver Dis2016;48:197-202

[45] Suminami Y,Murakami A,Gondo T,Numa F,Kato H.Suppression of a squamous cell carcinoma (scc)-related serpin, scc antigen, inhibits tumor growth with increased intratumor infiltration of natural killer cells.Cancer Res2001;61:1776-80

[46] Martini A,Pontisso P.Clinical applications of squamous cell carcinoma antigen-immunoglobulins M to monitor chronic hepatitis C.World J Hepatol2015;7:2913-9 PMCID:PMC4678378

[47] Novo E,Turato C,Paternostro C,Biasiolo A,Morello E,Miglietta A,Sutti S,Albano E,Pontisso P.SerpinB3 promotes pro-fibrogenic responses in activated hepatic stellate cells.Sci Rep2017;7:3420 PMCID:PMC5469760

[48] Pozzan C,Piciocchi M,Maddalo G,Giacomin A,Cillo U.Diagnostic and prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma (HCC).J Gastroenterol Hepatol2014;29:1637-44

[49] Heitzer E,Geigl JB.The potential of liquid biopsies for the early detection of cancer.NPJ Precis Oncol2017;1:36 PMCID:PMC5871864

[50] Crowley E,Loupakis F.Liquid biopsy: monitoring cancer-genetics in the blood.Nat Rev Clin Oncol2013;10:472-84

[51] Bardelli A.Liquid biopsies, what we do not know (yet).Cancer Cell2017;31:172-9

[52] Alix-Panabières C.Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy.Cancer Discov2016;6:479-91

[53] Okajima W,Ichikawa D,Ohashi T,Kiuchi J,Arita T,Shiozaki A,Ikoma H,Otsuji E.Liquid biopsy in patients with hepatocellular carcinoma: circulating tumor cells and cell-free nucleic acids.World J Gastroenterol2017;23:5650-68 PMCID:PMC5569280

[54] Yin CQ,Qu Z,Chen H.Liquid biopsy of hepatocellular carcinoma: circulating tumor-derived biomarkers.Dis Markers2016;2016:1427849 PMCID:PMC4925990

[55] Zhou J,Yang XR.Liquid biopsy and its potential for management of hepatocellular carcinoma.J Gastrointest Cancer2016;47:157-67

[56] Labgaa I.Liquid biopsy in liver cancer.Discov Med2015;105:263-73

[57] Chaffer CL.A perspective on cancer cell metastasis.Science2011;331:1559-64

[58] Jiang Y.Liquid biopsy in the OMICS era of tumor medicine.Open Access J Biomed Eng Appl2018;1:115 PMCID:PMC5908475

[59] Ashworth T.A case of cancer in which cells similar to those in the tumours were seen in the blood after death.Aust Med J1869;14:146-9

[60] Miller MC,Terstappen LW.Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer.J Oncol2010;2010:1-8 PMCID:PMC2793426

[61] Vona G,Béroud C,Capron F,Mineur A,Lacour B,Bréchot C.Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer.Hepatology2004;39:792-7

[62] Krebs MG,Carter L,Blackhall FH.Molecular analysis of circulating tumour cells - biology and biomarkers.Nat Rev Clin Oncol2014;11:129-44

[63] Wu LJ,Pei XY,Nguyen S,Liu J.Capturing circulating tumor cells of hepatocellular carcinoma.Cancer Lett2012;326:17-22

[64] Thompson EW.The social aspects of EMT-MET plasticity.Nat Med2011;17:1048-9

[65] Guo W,Sun YF,Ma XL,Zhang CY,Xu Y,Zhang X,Fan J.Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform.Clin Cancer Res2014;20:4794-805

[66] Nagrath S,Maheswaran S,Irimia D,Smith MR,Digumarthy S,Ryan P,Tompkins RG.Toner MIsolation of rare circulating tumour cells in cancer patients by microchip technology..Nature2007;450:1235-9 PMCID:PMC3090667

[67] Xu W,Chen L,Zhang XF,Kang XY,Liao J,Yang YF,Yin ZF.Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy.Clin Cancer Res2011;17:3783-93

[68] Olthoff KM,Hübscher S.What is the best staging system for hepatocellular carcinoma in the setting of liver transplantation?.Liver Transpl2011;17 Suppl 2:S26-33

[69] Fan JL,Yuan CH,Wang FB.Circulating tumor cells for predicting the prognostic of patients with hepatocellular carcinoma: a meta analysis.Cell Physiol Biochem2015;37:629-40

[70] Fan ST,Ho DWY,Yu WC.Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: a prospective study.Ann Surg2011;254:569-76

[71] Kim MY,Acharyya S,Zhang XHF,Massagué J.Tumor self-seeding by circulating cancer cells.Cell2009;139:1315-26 PMCID:PMC2810531

[72] Pantel K,Brandt B.Detection, clinical relevance and specific biological properties of disseminating tumour cells.Nat Rev Cancer2008;8:329-40

[73] Leon SA,Sklaroff DM.Free DNA in the serum of cancer patients and the effect of therapy.Cancer Res1977;37:646-50

[74] Tang JC,Guo T,Cai XJ.Circulating tumor DNA in hepatocellular carcinoma: trends and challenges.Cell Biosci2016;6:32 PMCID:PMC4866298

[75] Heitzer E,Geigl JB.Circulating tumor DNA as a liquid biopsy for cancer.Clin Chem2015;61:112-23

[76] Sausen M,Adleff V,Leary RJ,Anagnostou V,Murphy D,Hruban CA,White JR,Allen PJ,Thompson CB,Linehan DC,Hruban RH,Von Hoff DD,Drebin JA.Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients.Nat Commun2015;6:7686 PMCID:PMC4634573

[77] Huang Z,Hu Y,Zhou X,Wang Q,Du X.Quantitation of plasma circulating DNA using quantitative PCR for the detection of hepatocellular carcinoma.Pathol Oncol Res2012;18:271-6

[78] Chen H,Zheng H,Jin X.Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma.Pathology2012;44:318-24

[79] Mohamed NA,Amin NF,Tag-Eldin LM.Is serum level of methylated RASSF1A valuable in diagnosing hepatocellular carcinoma in patients with chronic viral hepatitis C?.Arab J Gastroenterol2012;13:111-5

[80] Sun FK,Zhao J,Gao S,Sun Q.Detection of TFPI2 methylation in the serum of hepatocellular carcinoma patients.Dig Dis Sci2013;58:1010-5

[81] Earl J,Martinez-Avila JC,Sanjuanbenito A,Lisa E,Lobo E,Carrato A.Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.BMC Cancer2015;15:797 PMCID:PMC4619983

[82] Kinugasa H,Miyahara K,Dohi C,Kato H,Okada H.Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer.Cancer2015;121:2271-80

[83] Villar S,Gouas DA,Ferro G,Lereau M,Hall AJ,Mendy M,van der Sande M,Friesen MD,Hainaut P.Seasonal variation in Tp53 R249S-mutated serum DNA with aflatoxin exposure and hepatitis B virus infection.Environ Health Perspect2011;119:1635-40 PMCID:PMC3226502

[84] Kirk GD,Mendy M,Whittle H,Hainaut P.249ser TP53 mutation in plasma DNA, hepatitis B viral infection, and risk of hepatocellular carcinoma.Oncogene2005;24:5858-67

[85] Hosny G,Tayel H.Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases.Cancer Lett2008;264:201-8

[86] Hu J,Fan J,He Y,Huang X,Xiao Y,Shi Y,Yang X,Yu L,Ding Z,Tang Z.Genetic variations in plasma circulating DNA of HBV-related hepatocellular carcinoma patients predict recurrence after liver transplantation.PLoS One2011;6:e26003 PMCID:PMC3187841

[87] García-Fernández N,Rubio A,Bellido-Díaz ML,Molinero P,Suárez-Artacho G.Detection of p53 mutations in circulating DNA of transplanted hepatocellular carcinoma patients as a biomarker of tumor recurrence.Adv Exp Med Biol2016;924:25-8

[88] Labgaa I,D'Avola D,von Felden J,Sia D,Ward SC,Mahajan M,Thung SN,Friedman SL,Schwartz M.A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.Oncogene2018;

[89] Chan KCA,Mok TSK,Ding C,Lo YMD.Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma.Clin Chem2008;54:1528-36

[90] Huang ZH,Hua D,Song MX.Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma.Exp Mol Pathol2011;91:702-7

[91] Huang A,Zhou SL,Huang XW,Yang XR.Detecting circulating tumor DNA in hepatocellular carcinoma patients using droplet digital PCR is feasible and reflects intratumoral heterogeneity.J Cancer2016;7:1907-14 PMCID:PMC5039376

[92] Xu RH,Krawczyk M,Luo H,Yi S,Quan Q,Zheng L,Caughey BA,Hou J,Xu Y,Li G,Zhong Z,X2 Fu,Duan Y,Ying B,Wang J,Zhang C,Guo R,Zhu JK,Zhang K.Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma.Nat Mater2017;16:1155-61

[93] Chen ZZ,Wu YH,Zhu PP.LncSox4 promotes the self-renewal of liver tumour-initiating cells through Stat3-mediated Sox4 expression.Nat Commun2016;7:12598 PMCID:PMC4999516

[94] Yuan SX,Yang F,Zhang J,Yang Y,Wang guang Z,Fan J,Sun SH.Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1.Hepatology2016;63:499-511

[95] Cao C,Zhang D,Xie L,Wu D.The long intergenic noncoding RNA UFC1, a target of microRNA 34a, interacts with the mRNA stabilizing protein HuR to increase levels of β-catenin in HCC cells.Gastroenterology2015;148:415-26

[96] Guo W,Cheng Y,Shi J,Li N,Wu M,Liu S.ICAM-1-related noncoding RNA in cancer stem cells maintains ICAM-1 expression in hepatocellular carcinoma.Clin Cancer Res2016;22:2041-50

[97] Wang X,Shen W,Chen C,Ning B,Li H,Ding J.Long non-coding RNA DILC regulates liver cancer stem cells via IL-6/STAT3 axis.J Hepatol2016;64:1283-94

[98] Zhou CC,Yuan x S,Liu F,Bi FR,Yin JH,Zhou WP,Sun SH.Systemic genome screening identifies the outcome associated focal loss of long noncoding RNA PRAL in hepatocellular carcinoma..Hepatology2016;63:850-63

[99] Romano G,Acunzo M.Small non-coding RNA and cancer.Carcinogenesis2017;38:485-91

[100] Bala S,Mundkur S,Levin I,Alao H,Szabo G.Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases.Hepatology2012;56:1946-57 PMCID:PMC3486954

[101] Jiang L,Cheng Q.Plasma microRNA might as a potential biomarker for hepatocellular carcinoma and chronic liver disease screening.Tumour Biol2015;36:7167-74

[102] Raposo G.Extracellular vesicles: exosomes, microvesicles, and friends.J Cell Biol2013;200:373-83 PMCID:PMC3575529

[103] Théry C,Amigorena S.Exosomes: composition, biogenesis and function.Nat Rev Immunol2002;2:569-79

[104] Yang X,Xiao YF,Hu CJ,Li BS.The emergence of long non-coding RNAs in the tumorigenesis of hepatocellular carcinoma.Cancer Lett2015;360:119-24

[105] Qiu MT,Yin R.Long noncoding RNA: an emerging paradigm of cancer research.Tumor Biol2013;34:613-20

[106] Lu J,Geng L,Sui C.Investigation of serum lncRNA-uc003wbd and lncRNA-AF085935 expression profile in patients with hepatocellular carcinoma and HBV.Tumor Biol2015;36:3231-6

[107] Tang J,Zhang X,Ji J,Qian X,Sun B.A novel biomarker Linc00974 interacting with KRT19 promotes proliferation and metastasis in hepatocellular carcinoma.Cell Death Dis2014;5:e1549 PMCID:PMC4649834

[108] Jing W,Zhu M,Jing X,Tu J.Potential diagnostic value of lncRNA SPRY4-IT1 in hepatocellular carcinoma.Oncol Rep2016;36:1085-92

[109] Li SP,Yu Y,Wang Z,Wang CY,Zhang RX,Yao Z.LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway.Oncotarget2016;7:42431-46

[110] Xie H,Zhou D.Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma.Biomed Res Int2013;2013:136106 PMCID:PMC3674644

[111] Lachenmayer A,Savic R,Toffanin S,Villanueva A,Newell P,Barretina J,Ward SC,Mazzaferro V,Friedman SL.Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.Clin Cancer Res2012;18:4997-5007 PMCID:PMC3446854

[112] Ma X,Yang C,Han B,Zhuang L.DANCR acts as a diagnostic biomarker and promotes tumor growth and metastasis in hepatocellular carcinoma.Anticancer Res2016;36:6389-98

[113] El-Tawdi AHF,El-Nakeep S,Abdel-Rahman O.Association of long noncoding RNA and c-JUN expression in hepatocellular carcinoma.Expert Rev Gastroenterol Hepatol2016;10:869-77

[114] Kamel MM,Sallam M,Saad AS.Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma.Transl Res2016;168:134-45

[115] Klingenberg M,Diederichs S.Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets.J Hepatol2017;67:603-18

[116] Coulouarn C,Andersen JB,Thorgeirsson SS.Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties.Oncogene2009;28:3526-36 PMCID:PMC3492882

[117] Luo J,Huang H,Zhang M,Deng S.Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma.Onco Targets Ther2013;6:577-83 PMCID:PMC3666878

[118] Xu J,Che X,Yu D,Huang L,Tan W,Lin D.Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis.Mol Carcinog2011;50:136-42

[119] Kojima K,Vadnais C,Yoshikawa T,Kondo Y,Kishikawa T,Xie Z,Yoshida H,Nepveu A.MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma.Nat Commun2011;2:338

[120] Tan Y,Pan T,Chen L,Zhou X.A serum microrna panel as potential biomarkers for hepatocellular carcinoma related with hepatitis b virus.PLoS One2014;9:e66577 PMCID:PMC4169601

[121] Ali HEA,Effat H,Atef AA,Ali M,Abdel Wahab AH.Circulating microRNAs panel as a diagnostic tool for discrimination of HCV-associated hepatocellular carcinoma.Clin Res Hepatol Gastroenterol2017;41:e51-62

[122] Zekri ARN,El-Desouky ED,Lotfy MM,Bahnassey AA.Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection.Tumor Biol2016;37:12273-86

[123] El-Tawdi AHF,Shehata HH,El-Khazragy N,Abdel-Rahman O.Evaluation of circulatory RNA-based biomarker panel in hepatocellular carcinoma.Mol Diagnosis Ther2016;20:265-77

[124] Okajima W,Ichikawa D,Kawaguchi T,Ohashi T,Kiuchi J,Konishi H,Moriumura R,Okamoto K,Itoh Y.Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function.Oncotarget2016;7:53820-36 PMCID:PMC5288224

[125] Tomimaru Y,Nagano H,Kobayashi S,Tanemura M,Takemasa I,Kanto T,Mori M.Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma.J Hepatol2012;56:167-75

[126] Huang JT,Ma H,Zhang X,Zhang X,Wang J.Systematic review and meta-analysis: circulating miRNAs for diagnosis of hepatocellular carcinoma.J Cell Physiol2016;231:328-35

[127] Zhou L,Song WJ,Yang F,Zhang N.MicroRNA-21 regulates the migration and invasion of a stem-like population in hepatocellular carcinoma.Int J Oncol2013;43:661-9

[128] Wang J,Shen J,Yang L.MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma.BMC Cancer2012;12:227 PMCID:PMC3492170

[129] Becker A,Weiss JM,Peinado H.Extracellular vesicles in cancer: cell-to-cell mediators of metastasis.Cancer Cell2016;30:836-48 PMCID:PMC5157696

[130] Jia S,Samuels ML,Chammas R,Zarovni N,Kuo WP.Emerging technologies in extracellular vesicle-based molecular diagnostics.Expert Rev Mol Diagn2014;14:307-21

[131] Wendler F,Simon T,Stebbing J.Extracellular vesicles swarm the cancer microenvironment: from tumor-stroma communication to drug intervention.Oncogene2017;36:877-84

[132] Witwer KW,Bemis LT,Lässer C,Nolte-’t Hoen EN,Sivaraman S,Théry C,Hochberg F.Standardization of sample collection, isolation and analysis methods in extracellular vesicle research.J Extracell Vesicles2013;2:20360 PMCID:PMC3760646

[133] Conde-Vancells J,Embade N,Matthiesen R,Elortza F,Mato JM.Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes.J Proteome Res2008;7:5157-66 PMCID:PMC2696236

[134] Willms A,Julich H,Schwab R,Richardsen I,Krawczyk M,Lammert F,Lukacs-Kornek V.Tumour-associated circulating microparticles: a novel liquid biopsy tool for screening and therapy monitoring of colorectal carcinoma and other epithelial neoplasia.Oncotarget2016;7:30867-75 PMCID:PMC5058724

[135] Abbate V,Giuliante F,Gatto I,Saviano A,Gaetani E,Giarretta I,Riccardi L,Ponziani FR,Pompili M.HepPar1-positive circulating microparticles are increased in subjects with hepatocellular carcinoma and predict early recurrence after liver resection.Int J Mol Sci2017;18:E1043 PMCID:PMC5454955

[136] Kornek M,Mehta SH,Exley M,Schuppan D.Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis.Gastroenterology2012;143:448-58 PMCID:PMC3404266

[137] Julich-Haertel H,Krawczyk M,Jankowski K,Kruk B,Ligocka J,Richardsen I,Klein A,Sänger H,Banales JM,Milkiewicz P,Krawczyk M,Kornek M.Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma.J Hepatol2017;67:282-92

[138] Berhane S,Tada T,Kagebayashi C,Schweitzer N,Manns MP,Berg T,Best J,Gerken G,Weinmann A,Galle P,Mo F,Reeves H,Johnson P.Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients.Clin Gastroenterol Hepatol2016;14:875-86.e6